Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980 Jun;9(6):614–618. doi: 10.1111/j.1365-2125.1980.tb01090.x

Plasma binding of disopyramide.

B M David, B W Madsen, K F Ilett
PMCID: PMC1430006  PMID: 7387819

Full text

PDF
616

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borgå O., Piafsky K. M., Nilsen O. G. Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):539–544. [PubMed] [Google Scholar]
  2. Brand J. G., Toribara T. Y. Equilibrium dialysis and circular dichroic analysis of the novobiocin-human serum albumin complex. Arch Biochem Biophys. 1975 Mar;167(1):91–98. doi: 10.1016/0003-9861(75)90444-0. [DOI] [PubMed] [Google Scholar]
  3. Chien Y. W., Lambert H. J., Karim A. Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins. J Pharm Sci. 1974 Dec;63(12):1877–1879. doi: 10.1002/jps.2600631210. [DOI] [PubMed] [Google Scholar]
  4. Cunningham J. L., Shen D. D., Shudo I., Azarnoff D. L. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet. 1977 Sep-Oct;2(5):373–383. doi: 10.2165/00003088-197702050-00004. [DOI] [PubMed] [Google Scholar]
  5. Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs. 1978 May;15(5):331–368. [PubMed] [Google Scholar]
  6. Hinderling P. H., Bres J., Garrett E. R. Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite. J Pharm Sci. 1974 Nov;63(11):1684–1690. doi: 10.1002/jps.2600631103. [DOI] [PubMed] [Google Scholar]
  7. Hinderling P. H., Garrett E. R. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm. 1976 Jun;4(3):199–230. doi: 10.1007/BF01063614. [DOI] [PubMed] [Google Scholar]
  8. Ilett K. F., Madsen B. W., Woods J. D. Disopyramide kinetics in patients with acute myocardial infarction. Clin Pharmacol Ther. 1979 Jul;26(1):1–7. doi: 10.1002/cpt19792611. [DOI] [PubMed] [Google Scholar]
  9. Johansson B. G., Kindmark C. O., Trell E. Y., Wollheim F. A. Sequential changes of plasma proteins after myocardial infarction. Scand J Clin Lab Invest Suppl. 1972;124:117–126. doi: 10.3109/00365517209102759. [DOI] [PubMed] [Google Scholar]
  10. Karim A., Kook C., Novotney R. L., Zagarella J., Campion J. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. Drug Metab Dispos. 1978 May-Jun;6(3):338–345. [PubMed] [Google Scholar]
  11. Meffin P. J., Robert E. W., Winkle R. A., Harapat S., Peters F. A., Harrison D. C. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm. 1979 Feb;7(1):29–46. doi: 10.1007/BF01059439. [DOI] [PubMed] [Google Scholar]
  12. Smith S. J., Bos G., Esseveld M. R., Van Eijk H. G., Gerbrandy J. Acute-phase proteins from the liver and enzymes from myocardial infarction; a quantitative relationship. Clin Chim Acta. 1977 Nov 15;81(1):75–85. doi: 10.1016/0009-8981(77)90415-6. [DOI] [PubMed] [Google Scholar]
  13. Ward J. W., Kinghorn G. R. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens. J Int Med Res. 1976;4(1 Suppl):49–53. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES